Celldex Therapeutics (CLDX) Other Operating Expenses (2010 - 2023)

Celldex Therapeutics' Other Operating Expenses history runs 14 years deep, the most recent figure standing at $12.5 million for Q4 2023.

• On a quarterly basis, Other Operating Expenses rose 32794.74% year-over-year to $12.5 million in Q4 2023; TTM through Sep 2024 was $12.5 million, a 32794.74% increase from a year earlier, with the FY2023 full-year figure at -$12.5 million, down 281.16% from the prior year.
• Other Operating Expenses advanced to $12.5 million in Q4 2023 per CLDX's latest filing, from $38000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $12.5 million in Q4 2023 and bottomed at -$1.5 million in Q1 2019.
• The 5-year median for Other Operating Expenses is $121500.0 (2021), against an average of $1.6 million.
• Across the five-year window, Other Operating Expenses plunged 133.11% in 2020 and surged 32794.74% in 2023, its largest moves.
• Year by year, Other Operating Expenses stood at -$318000.0 in 2019, then surged by 105.66% to $18000.0 in 2020, then surged by 1038.89% to $205000.0 in 2021, then plunged by 81.46% to $38000.0 in 2022, then jumped by 32794.74% to $12.5 million in 2023.
• Per Business Quant, the three latest CLDX Other Operating Expenses figures stand at $12.5 million (Q4 2023), $38000.0 (Q4 2022), and $6.3 million (Q2 2022).